IP InterviewPublished November 17, 2020
Illumina & The Evolution of Next-Generation Sequencing
inpractise.com/articles/illumina-next-generation-sequencing
Executive Bio
Dale Yuzuki
Former Director at Illumina, Thermo Fisher Scientific and Pillar Biosciences
Why is this interview interesting?
- How the market evolved from microarrays to next-gen sequencing
- Risk of obsolescence of biotechnology
- Why Solexa’s intellectual property is unique and how they entered NGS
- Why Life Technology couldn’t compete with Solexa’s technology
- Use cases of long vs short read sequencing
- The competitive advantage of Illumina in short-read NGS
- Potential risks and opportunity for GRAIL
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content
Porvair & Chromatography Lab Equipment: M&A Process & Culture
Former Senior Vice President Life Sciences at J.G. Finneran, Porvair plc
Thermo Fisher Scientific Inc: Culture and Management
Former Director at Thermo Fisher Scientific
Thermo Fisher vs Danaher: Business Model and Competitive Positioning
Former Director, Corporate Strategy & Business Development at Thermo Fisher Scientific
Danaher, Aldevron, Intangible & Goodwill Impairments
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.